On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: Study protocol for a hybrid design randomized controlled trial

Jemima A. Frimpong, Thomas D'Aunno, David C. Perlman, Shiela M. Strauss, Alissa Mallow, Diana Hernandez, Bruce R. Schackman, Daniel J. Feaster, Lisa R. Metsch

Research output: Contribution to journalArticle

Abstract

Background: More than 1.2 million people in the United States are living with human immunodeficiency virus (HIV), and 3.2 million are living with hepatitis C virus (HCV). An estimated 25% of persons living with HIV also have HCV. It is therefore of great public health importance to ensure the prompt diagnosis of both HIV and HCV in populations that have the highest prevalence of both infections, including individuals with substance use disorders (SUD). Methods/design: In this theory-driven, efficacy-effectiveness-implementation hybrid study, we will develop and test an on-site bundled rapid HIV/HCV testing intervention for SUD treatment programs. Its aim is to increase the receipt of HIV and HCV test results among SUD treatment patients. Using a rigorous process involving patients, providers, and program managers, we will incorporate rapid HCV testing into evidence-based HIV testing and linkage to care interventions. We will then test, in a randomized controlled trial, the extent to which this bundled rapid HIV/HCV testing approach increases receipt of HIV and HCV test results. Lastly, we will conduct formative research to understand the barriers to, and facilitators of, the adoption, implementation, and sustainability of the bundled rapid testing strategy in SUD treatment programs. Discussion: Novel approaches that effectively integrate on-site rapid HIV and rapid HCV testing are needed to address both the HIV and HCV epidemics. If feasible and efficacious, bundled rapid HIV/HCV testing may offer a scalable, potentially cost-effective approach to testing high-risk populations, such as patients of SUD treatment programs. It may ultimately lead to improved linkage to care and progress through the HIV and HCV care and treatment cascades. Trial registration: ClinicalTrials.gov: NCT02355080. (30 January 2015)

Original languageEnglish (US)
Article number117
JournalTrials
Volume17
Issue number1
DOIs
StatePublished - Mar 3 2016

Fingerprint

Hepacivirus
Substance-Related Disorders
Randomized Controlled Trials
HIV
Therapeutics
Population
Public Health
Costs and Cost Analysis

Keywords

  • Adoption of evidence-based practices
  • Bundled HIV/HCV testing
  • HCV testing
  • HIV testing
  • Hybrid intervention-implementation research
  • Implementation research
  • Intervention adaptation
  • Substance use disorder treatment

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs : Study protocol for a hybrid design randomized controlled trial. / Frimpong, Jemima A.; D'Aunno, Thomas; Perlman, David C.; Strauss, Shiela M.; Mallow, Alissa; Hernandez, Diana; Schackman, Bruce R.; Feaster, Daniel J.; Metsch, Lisa R.

In: Trials, Vol. 17, No. 1, 117, 03.03.2016.

Research output: Contribution to journalArticle

Frimpong, JA, D'Aunno, T, Perlman, DC, Strauss, SM, Mallow, A, Hernandez, D, Schackman, BR, Feaster, DJ & Metsch, LR 2016, 'On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: Study protocol for a hybrid design randomized controlled trial', Trials, vol. 17, no. 1, 117. https://doi.org/10.1186/s13063-016-1225-4
Frimpong, Jemima A. ; D'Aunno, Thomas ; Perlman, David C. ; Strauss, Shiela M. ; Mallow, Alissa ; Hernandez, Diana ; Schackman, Bruce R. ; Feaster, Daniel J. ; Metsch, Lisa R. / On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs : Study protocol for a hybrid design randomized controlled trial. In: Trials. 2016 ; Vol. 17, No. 1.
@article{0510a52d3317491dbf315f88c3e82541,
title = "On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: Study protocol for a hybrid design randomized controlled trial",
abstract = "Background: More than 1.2 million people in the United States are living with human immunodeficiency virus (HIV), and 3.2 million are living with hepatitis C virus (HCV). An estimated 25{\%} of persons living with HIV also have HCV. It is therefore of great public health importance to ensure the prompt diagnosis of both HIV and HCV in populations that have the highest prevalence of both infections, including individuals with substance use disorders (SUD). Methods/design: In this theory-driven, efficacy-effectiveness-implementation hybrid study, we will develop and test an on-site bundled rapid HIV/HCV testing intervention for SUD treatment programs. Its aim is to increase the receipt of HIV and HCV test results among SUD treatment patients. Using a rigorous process involving patients, providers, and program managers, we will incorporate rapid HCV testing into evidence-based HIV testing and linkage to care interventions. We will then test, in a randomized controlled trial, the extent to which this bundled rapid HIV/HCV testing approach increases receipt of HIV and HCV test results. Lastly, we will conduct formative research to understand the barriers to, and facilitators of, the adoption, implementation, and sustainability of the bundled rapid testing strategy in SUD treatment programs. Discussion: Novel approaches that effectively integrate on-site rapid HIV and rapid HCV testing are needed to address both the HIV and HCV epidemics. If feasible and efficacious, bundled rapid HIV/HCV testing may offer a scalable, potentially cost-effective approach to testing high-risk populations, such as patients of SUD treatment programs. It may ultimately lead to improved linkage to care and progress through the HIV and HCV care and treatment cascades. Trial registration: ClinicalTrials.gov: NCT02355080. (30 January 2015)",
keywords = "Adoption of evidence-based practices, Bundled HIV/HCV testing, HCV testing, HIV testing, Hybrid intervention-implementation research, Implementation research, Intervention adaptation, Substance use disorder treatment",
author = "Frimpong, {Jemima A.} and Thomas D'Aunno and Perlman, {David C.} and Strauss, {Shiela M.} and Alissa Mallow and Diana Hernandez and Schackman, {Bruce R.} and Feaster, {Daniel J.} and Metsch, {Lisa R.}",
year = "2016",
month = "3",
day = "3",
doi = "10.1186/s13063-016-1225-4",
language = "English (US)",
volume = "17",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs

T2 - Study protocol for a hybrid design randomized controlled trial

AU - Frimpong, Jemima A.

AU - D'Aunno, Thomas

AU - Perlman, David C.

AU - Strauss, Shiela M.

AU - Mallow, Alissa

AU - Hernandez, Diana

AU - Schackman, Bruce R.

AU - Feaster, Daniel J.

AU - Metsch, Lisa R.

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Background: More than 1.2 million people in the United States are living with human immunodeficiency virus (HIV), and 3.2 million are living with hepatitis C virus (HCV). An estimated 25% of persons living with HIV also have HCV. It is therefore of great public health importance to ensure the prompt diagnosis of both HIV and HCV in populations that have the highest prevalence of both infections, including individuals with substance use disorders (SUD). Methods/design: In this theory-driven, efficacy-effectiveness-implementation hybrid study, we will develop and test an on-site bundled rapid HIV/HCV testing intervention for SUD treatment programs. Its aim is to increase the receipt of HIV and HCV test results among SUD treatment patients. Using a rigorous process involving patients, providers, and program managers, we will incorporate rapid HCV testing into evidence-based HIV testing and linkage to care interventions. We will then test, in a randomized controlled trial, the extent to which this bundled rapid HIV/HCV testing approach increases receipt of HIV and HCV test results. Lastly, we will conduct formative research to understand the barriers to, and facilitators of, the adoption, implementation, and sustainability of the bundled rapid testing strategy in SUD treatment programs. Discussion: Novel approaches that effectively integrate on-site rapid HIV and rapid HCV testing are needed to address both the HIV and HCV epidemics. If feasible and efficacious, bundled rapid HIV/HCV testing may offer a scalable, potentially cost-effective approach to testing high-risk populations, such as patients of SUD treatment programs. It may ultimately lead to improved linkage to care and progress through the HIV and HCV care and treatment cascades. Trial registration: ClinicalTrials.gov: NCT02355080. (30 January 2015)

AB - Background: More than 1.2 million people in the United States are living with human immunodeficiency virus (HIV), and 3.2 million are living with hepatitis C virus (HCV). An estimated 25% of persons living with HIV also have HCV. It is therefore of great public health importance to ensure the prompt diagnosis of both HIV and HCV in populations that have the highest prevalence of both infections, including individuals with substance use disorders (SUD). Methods/design: In this theory-driven, efficacy-effectiveness-implementation hybrid study, we will develop and test an on-site bundled rapid HIV/HCV testing intervention for SUD treatment programs. Its aim is to increase the receipt of HIV and HCV test results among SUD treatment patients. Using a rigorous process involving patients, providers, and program managers, we will incorporate rapid HCV testing into evidence-based HIV testing and linkage to care interventions. We will then test, in a randomized controlled trial, the extent to which this bundled rapid HIV/HCV testing approach increases receipt of HIV and HCV test results. Lastly, we will conduct formative research to understand the barriers to, and facilitators of, the adoption, implementation, and sustainability of the bundled rapid testing strategy in SUD treatment programs. Discussion: Novel approaches that effectively integrate on-site rapid HIV and rapid HCV testing are needed to address both the HIV and HCV epidemics. If feasible and efficacious, bundled rapid HIV/HCV testing may offer a scalable, potentially cost-effective approach to testing high-risk populations, such as patients of SUD treatment programs. It may ultimately lead to improved linkage to care and progress through the HIV and HCV care and treatment cascades. Trial registration: ClinicalTrials.gov: NCT02355080. (30 January 2015)

KW - Adoption of evidence-based practices

KW - Bundled HIV/HCV testing

KW - HCV testing

KW - HIV testing

KW - Hybrid intervention-implementation research

KW - Implementation research

KW - Intervention adaptation

KW - Substance use disorder treatment

UR - http://www.scopus.com/inward/record.url?scp=84959263846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959263846&partnerID=8YFLogxK

U2 - 10.1186/s13063-016-1225-4

DO - 10.1186/s13063-016-1225-4

M3 - Article

VL - 17

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 117

ER -